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Clinical and procedural characteristics and in-hospital complications
Variable
Commercial
Valve
(n37)
Cohort B
(n54) p value
Mean age (yearsSD) 838 837 0.87
Dialysis 11% 0 0.04
Conscious sedation 81% 56% 0.02
Planned surgical cut down 4% 85% 0.001
VARC major vascular complication 5% 22% 0.14
VARC life threatening bleed 9% 13% 0.69
Transfusion rates 27% 59% 0.007
Stroke 8% 11% 1
In-hospital mortality 2 0 0.1
Closure of Valve Leaks
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Background: Percutaneous transcatheter closure of Paravalvular leaks is a new alternative
approach to re-do surgery, which is associated with considerable mortality and morbidity.
We aim to evaluate feasibility and short term results with this novel closure technique.
Methods: Between May 2007 and September 2011. 16 symptomatic patients (seven
males, nine females; mean age 59.1  17.9 years) with heart failure (n9 ), hemolytic
anemia (n2) or both (n5) underwent percutaneous PVL closure at our center. Most
patients were high risk for open surgical repair (STS score 7.64  8.02) with average
number of sternotomies equal to 2.3 (range 0-4). Both left and right sided valves were
intervened upon including Mitral valves (n10), Aortic valves (n5), one of which was
a trans-catheter placed Sapien Valve, Pulmonic valves ( n1). The procedure was done
under echocardiographic and fluoroscopic guidance using the Amplatzer Septal Occluder,
Duct Occluder or Vascular Plug II.
Results: Successful percutaneous repair was achieved in 12 out of 16 patients (75%).
Failure to cross the leak with either the wire or the catheter occurred in two patients. In
the other two patients, device was deployed with residual moderate regurgitation. There
were no procedural or unexplained death, but there were two post procedural deaths, one
patient had severe septic shock and the other had cardiogenic shock prior to intervention.
No emergency surgery or device embolization occurred .One patient had an ischemic
stroke in the fifth post-operative day. One patient with multiple defects and a failed
attempt required an elective surgical repair to seal the leak.
Conclusions: Percutaneous transcatheter closure of paravalvular leaks is feasible but
appears to be technically demanding procedure with acceptable success rate especially in
poor surgical candidate. Further experience is warranted to evaluate long term morbidity
and mortality.
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Introduction: Functional Mitral Regurgitation (FMR) may cause Heart Failure (HF).
Cardiac surgery for open correction of FMR in patients with severely impaired left
ventricular ejection fraction (LVEF) or prior cardiac surgery entails higher risk. The
EVEREST II Trial in patients who were surgical candidates for mitral valve repair
showed outcomes of percutaneous repair using the MitraClip were comparable with
surgery.
Hypothesis: We hypothesized that MitraClip is safe and effective in patients with severe
FMR and HF who are not surgical candidates.
Methods: We identified 4 patients with significant FMR and limited exercise capacity
due to HF. Significant ischemia was excluded with functional imaging. Surgical risk was
deemed prohibitive. Mitral valve anatomy was assessed by transthoracic (TTE) and
transesophageal echocardiography.
Patients: One patient was female, 2 had AF, 3 had prior remote coronary artery bypass
graft surgery, and the 4th had non-ischemic cardiomyopathy. Age was 59  11 years,
BSA 1.7  0.1 m2, GFR 57.5  46.9mls/min, Hemoglobin 11.2  1.4g/dL. NYHA
2.75  0.5, LVEF 30  17%, MR grade 3.75  0.5, Six-Minute Walk Distance
(6MWD) 208  132m, and Euroscore risk for cardiac surgery 32.9  26.9%.
Results: All patients underwent successful MitraClip procedures without complication.
Three patients used 1 clip, while 1 patient required 2 clips. MR grade was reduced to
1.25  0.5 and patients were discharged 2.25  0.96 days post MitraClip. Follow-up
TTEs show durability of MR reduction (Fig 1.). 6MWD improved to 423  92m
(p0.037). Two patients have resumed working, and all can participate in normal
activities of daily living. They remain on standard pharmacotherapy for heart failure.
Conclusion: In conclusion, MitraClip is safe and effective in restoring exercise capacity
in selected patients with severe FMR and HF who are not surgical candidates.
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